Effects of iron deficiency and its treatment on fibroblast growth factor 23 (FGF23) in patients treated with chronic haemodialysis therapy

Next Previous
Trial Profile

Effects of iron deficiency and its treatment on fibroblast growth factor 23 (FGF23) in patients treated with chronic haemodialysis therapy

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Ferric carboxymaltose (Primary) ; Iron sucrose
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms D-IDENTIFY

    • Most Recent Events

    • 25 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top